It's a matter of weeks now until we begin to see: a) to what degree the H1N1 pandemic will again ramp up; b) which manufacturers will have developed vaccines in time to address the need; and c) if those vaccines will work against the dominant strain that develops.
Microsoft's Life Sciences Group has certainly grown, from 5 people when it was established seven years ago to 800 people today. The SharePoint platform, which allows users to customize solutions without having to play programmer is finding increased acceptance.
GlaxoSmithkline, Sanofi-Aventis, and Wyeth feel the pharmaceutical hurt as stocks continue to drop and FDA regulations continue to tighten. Investors are also facing confusion as FDA has begun to share preliminary drug information with the general public.
Yesterday's FDA panel rejection of Sanofi's weight loss drug Acomplia could mean trouble ahead for Pfizer and Merck, which are now in Phase III testing of drugs with similar modes of action (targeting endocannabinoid receptors), The Science Daily reported yesterday.